The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000465358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/03/2026
Date registered
Help: Date registered
15/04/2026
Date last updated
Help: Date last updated
15/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
15/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Trial to Evaluate the Safety and Feasibility of Belzupacap Sarotalocan (AU-011) for the Treatment of Conjunctival Melanoma, Melanocytic Lesions, or Conjunctival Squamous Cell Carcinoma in adult participants
Scientific title
A Phase 1 Open-Label Trial to Evaluate the Safety and Feasibility of Belzupacap Sarotalocan (AU-011) for the Treatment of Conjunctival Melanoma, Melanocytic Lesions, or Conjunctival Squamous Cell Carcinoma in adult participants.
Additional trial identifiers [1] 316454 0
AU-011-103
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Cancer of the ocular (eye) surface 340569 0
Conjunctival Melanoma 341123 0
Melanocytic Lesions 341124 0
Conjunctival Squamous Cell Carcinoma 341125 0
Condition category
Condition code
Eye 336769 336769 0 0
Diseases / disorders of the eye
Cancer 337233 337233 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The trial has 3 open-label arms based on the type of tumour present. Tumour arms will be assessed together.
- Elevated Conjunctival Melanoma (EM)
- Flat Conjunctival Melanoma (FM)
- Conjunctival Squamous cell carcinoma (SCC)

The allocation to each treatment group will be determined by the type of cancer the participant has.

There are 4 Cohorts in the study:
Cohort 1: Participants in the EM, SCC and FM arms will receive a single 100ug injection of study drug bel-sar followed by laser application approximately 4 to 6 hours post-injection (wavelength 689 nm, intensity-at-target 600 mW/cm2, and fluence-at-target 50 J/cm2).

Cohort 1a: Participants in the EM, SCC and FM arms will receive a single 40ug injection of study drug bel-sar followed by laser application approximately 4 to 6 hours post-injection (wavelength 689 nm, intensity-at-target 600 mW/cm2, and fluence-at-target 50 J/cm2).

Cohort 2: Participants in the EM, SCC and FM arms will receive two 100ug injections of study drug bel-sar, each injection followed by laser application approximately 4 to 6 hours post-injection (wavelength 689 nm, intensity-at-target 600 mW/cm2, and fluence-at-target 50 J/cm2). The second treatment will be adminstered 7 days after the first treatment.

Cohort 1b: Participants in the EM, SCC and FM arms will receive two 40ug injections of study drug bel-sar followed by laser application approximately 4 to 6 hours post-injection (wavelength 689 nm, intensity-at-target 600 mW/cm2, and fluence-at-target 50 J/cm2). The second treatment will be adminstered 7 days after the first treatment.

At the completetion of each Cohort, there will be an Safety Review Board (SRB) review and there will be independent dose modifications as appropriate. Treatment (bel-sar and laser application) will be administered by an ophthalmologist in the research clinic and adherence will monitored by site staff. Cohort allocation is determined by the type of cancer the patient has, and the timing of participation and the study cohort currently active.

Participants will undergo scheduled standard of care (SOC) tumour excision after the Cohort treatment is completed.
Intervention code [1] 333122 0
Treatment: Drugs
Intervention code [2] 333126 0
Treatment: Devices
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344291 0
Cohorts 1 and 1a - To determine the safety and feasibility of bel-sar treatment. Safety and tolerability will be assessed as a composite primary outcome.
Timepoint [1] 344291 0
In Cohorts 1 and 1a, AEs will be assessed at each visit and the severity of each AE and SAE will be assessed continuously as they are reported or observed and reviewed daily up until end of treatment (EOT) visit. AEs will be assessed at screening, day 1, day 2, the day of tumour excision, 14 days post tumour excision and then 90 days post-excision (EOT) visit. Vital signs will be assessed at screening, the day before the tumour excision and then 90 days post-excision (EOT) visits. Blood tests will be assessed at screening, the day before tumour excision and then 90 days post-excision (EOT visit). Visual acuity will be assessed at screening, the day of treatment, the day before tumour excision and then 90 days post-excision (EOT visit).
Primary outcome [2] 344789 0
Cohorts 2 and 1b - To determine the safety and feasibility of bel-sar treatment. Safety and tolerability will be assessed as a composite primary outcome.
Timepoint [2] 344789 0
In Cohorts 2 and 1b, AEs will be assessed at each visit and the severity of each AE and SAE will be assessed continuously as they are reported or observed and reviewed daily up until end of treatment (EOT) visit. AEs will be assessed at screening, day 1, day 2, day 8, day 9, the day of the tumour excision, 14 days post tumour excision and then 90 days post-excision (EOT visit). Vital signs will be assessed at screening, the day before tumour excision and then 90 days post-excision (EOT visit). Blood tests will be assessed at screening, the day before tumour excision and then 90 days post-excision (EOT visit). Visual acuity will be assessed at screening, the day of treatment, the day before tumour excision and then 90 days post-excision (EOT visit).
Secondary outcome [1] 457372 0
To assess the pharmacokinetics (PK) of bel-sar (AUC, Cmax, Tmax, T1/2).
Timepoint [1] 457372 0
Blood samples will be collected on the day of treatment and the day before excision.

Eligibility
Key inclusion criteria
Participants must:
1. Be at least 18 years of age.
2. Signed the informed consent form (ICF).
3. A confirmed diagnosis of EM, FM or SCC based on results of biopsy at Screening.
4. Have a new or recurrent tumour that currently meets eligibility criteria for the study tumour and planned tumour excision.
5. Have at least 1 conjunctival tumour (i.e., the selected study tumour) deemed suitable for a bel-sar injection
6. If born female and capable of becoming pregnant, have a negative pregnancy test at Screening and within 1 calendar day before bel-sar administration and must agree to use a highly effective method of contraception from the date of the screening pregnancy test through 90 days after the final dose of bel-sar.
7. If born male and of reproductive potential with sexual partner(s) of childbearing potential, must agree to use a highly effective form of birth control from before administration of the first dose of bel-sar through 90 days after the final dose of bel-sar.
8. Be able and willing to avoid all prohibited medications for the appropriate washout period as further clarified in the exclusion criteria.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants must not:
1. Have any ocular infection or an ocular disease other than the conjunctival tumour, that might progress during the trial and result in a change in vision, loss of vision, or confound trial assessments.
2. Have a conjunctival tumour extending within the central 6-mm diameter of the cornea selected as the study tumour.
3. Have had an ocular surgical procedure within 3 months of Screening.
4. Use of heparin or low molecular weight heparins within 1 week of bel-sar treatment or use of pentosan polysulfate within 1 year of Screening.
5. Must not have any additional malignancy that requires active treatment.
6. Have a known immune-deficiency state/myelodysplastic disorder, bone marrow failure, human immunodeficiency virus (HIV) infection, history of solid organ transplant or bone marrow allograft, or recent pregnancy.
7. Have an active bacterial, fungal, or viral infection.
8. Have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that, in the opinion of the Investigator may increase the risk associated with trial participation, or interfere with evaluation of bel-sar or interpretation of participant safety or trial results.
9. Have known hepatitis B or C infection.
10. Have used an investigational drug or medical device within 30 days or 5 half-lives (whichever is longer) of Screening or concurrently enrolled in another trial.
11. Have known contraindications or sensitivities to phthalocyanine-based dye, the capsid component in bel-sar, or to prior ocular treatment with laser.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD

Funding & Sponsors
Funding source category [1] 321063 0
Commercial sector/Industry
Name [1] 321063 0
Aura Biosciences, Inc.
Country [1] 321063 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Aura Biosciences, Inc.
Address
Country
United States of America
Secondary sponsor category [1] 323780 0
Commercial sector/Industry
Name [1] 323780 0
Avance Clinical Pty Ltd
Address [1] 323780 0
Country [1] 323780 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319601 0
Bellberry Human Research Ethics Committee F
Ethics committee address [1] 319601 0
Ethics committee country [1] 319601 0
Australia
Date submitted for ethics approval [1] 319601 0
28/01/2026
Approval date [1] 319601 0
13/03/2026
Ethics approval number [1] 319601 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147822 0
Dr Timothy Beckman
Address 147822 0
Queensland Ocular Oncology Service, Level 2, 87 Wickham Terrace, Spring Hill, Brisbane 4000
Country 147822 0
Australia
Phone 147822 0
+61 7 38310101
Fax 147822 0
Email 147822 0
Contact person for public queries
Name 147823 0
Auro Biosciences, Inc.
Address 147823 0
Aura Biosciences, Inc., 80 Guest Street, Boston, MA 02135, USA
Country 147823 0
United States of America
Phone 147823 0
+1 6175008864
Fax 147823 0
Email 147823 0
Contact person for scientific queries
Name 147824 0
Jill Hopkins, MD
Address 147824 0
Aura Biosciences, Inc., 80 Guest Street, Boston, MA 02135, USA
Country 147824 0
United States of America
Phone 147824 0
+1 6175008864
Fax 147824 0
Email 147824 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.